Clinical Features and Treatment Outcomes in Patients with Extracranial Germ Cell Tumors: A Tertiary Centre Experience

Pritanjali Singh¹, Dharmendra Singh²*, Jagjit Kumar Pandey³, Bindey Kumar⁴ and Avik Mandal²

¹Additional Professor, Department of Radiotherapy, All India Institute of Medical Sciences, Patna, Bihar, India
²Senior Resident, Department of Radiotherapy, All India Institute of Medical Sciences, Patna, Bihar, India
³Assistant Professor, Department of Surgical Oncology, All India Institute of Medical Sciences, Patna, Bihar, India
⁴Professor, Department of Pediatric Surgery, All India Institute of Medical Sciences, Patna, Bihar, India

ABSTRACT

Background: Germ cell tumors are histologically heterogeneous group of tumors with high cure rate if diagnosed early. The aim of study was to evaluate the extracranial germ cell tumors presenting to our institute with regards to gender, age, clinical presentation, pathology, management, acute toxicity and survival.

Material and Methods: This retrospective study was conducted at Department of Radiation Oncology, All India Institute of Medical Sciences (AIIMS), Patna.

Results: Total of 75 patients with germ cell tumor (GCT) were analysed. Distribution of males and females were 50.7% and 49.3% respectively. The median age of presentation of males and females was 31 years and 15 years respectively. At the time of presentation, 47.3% male and 16.2% of female patients had metastatic disease. The median alpha-fetoprotein (AFP), beta subunit of human chorionic gonadotropin (βHCG), and lactate dehydrogenase (LDH) were 112 ng/ml, 668 mIU/ml, and 550 U/L respectively. At median follow-up of 34 months, 32% of the patient developed recurrence. The median disease-free survival (DFS) and overall survival (OS) were 57 months and 71 months respectively. Multivariate analysis showed that the histological subtypes (p = 0.001) and risk groups (p = 0.029) were the independent prognostic factors for DFS, while metastatic status at presentation (p = 0.037), upfront surgical intervention (p =0.039), and histopathological subtypes (p = 0.009) were the independent prognostic factor for OS.

Conclusion: GCT is primarily a disease of young and adolescents. Early diagnosis, well-orchestrated multidisciplinary management leads to favourable outcome and survival.

© 2021 Dharmendra Singh. Hosting by Science Repository. All rights reserved.

Introduction

Germ cell tumors (GCT) are a heterogeneous group of tumors, which are curable. They arise from primordial germ cells that migrate during embryogenesis from yolk sac to the gonads. They are broadly classified into gonadal and extragonadal based on anatomy. Again, it can be classified into the following groups depending on pathology.

i. Teratoma,
ii. Malignant germ cell tumor
iii. Mixed GCT: a separate entity, which houses two different types

Teratoma can be divided into mature teratoma and immature teratoma. Malignant GCT is classified as seminomatous (ST) and nonseminomatous (NST) in males, dysgerminoma, and non-dysgerminomas in females that include yolk sac tumors, embryonal carcinoma, gonadoblastoma and choriocarcinoma.

Various registries throughout the world have different reported incidences of testicular GCT varying from 1.7 per 100,000 to 2.7 per 100,000 amongst males, from 15-39 years of age. The incidence is increasing according to many reports worldwide [1]. European Cancer
Regist:**o**y-Based Study on Survival and Care of Cancer Patients (EUROCARE) reports markedly distinct age-adjusted incidence rates of GCTs in Europe for males and females 64 per 1,000,000 versus 4 per 1,000,000, respectively. There is lack of Indian data. In general, 80% of GCT are benign, 20% are malignant. In the pediatric age group, 2.5% of malignant germ cell tumors are found [2]. Germ cell tumors usually occur in the second or third decade of life. Fertility sparing surgery is offered to all patients. Chemotherapy with platinum-based combinations has extended 5-year survival rates from 100% in stage I to approximately 75% in higher stages. Despite good clinical outcome, in developing countries such as ours there are many challenges we come across while treating patients especially since they present with advanced stage, heavy nodal burden and poor risk factors. In this study, we report our experience of extracranial germ cell tumors at a tertiary referral center, focussing on demography, histopathology, management, outcome and prognosis.

**Aim**

Aim of study was to evaluate the extracranial germ cell tumors presenting at our institute with regards to gender, age, clinical presentation, pathology, management, acute toxicity and survival.

**Materials and Methods**

**I Patients**

We conducted a tertiary hospital based retrospective study in the department of Radiation Oncology at AIIMS, Patna, wherein all cases of registered germ cell tumors during the period from August 2014 to March 2020 was retrieved from the recorded files and analysed. The study focused on demographic profile as well as clinical presentation with respect to age, presenting complaints, histological types and tumors markers, surgical procedures, systemic chemotherapy, toxicity and disease-free survival (DFS) and overall survival (OS) outcomes. A detailed history, physical examination, and performance status of all patients was recorded. Eastern Cooperative Oncology Group performance status (ECOG PS) scale was used for performance status. Radiological investigations included a contrast-enhanced computed tomography (CECT) of abdomen, pelvis and thorax in majority of the cases. Ultrasonography of the abdomen and chest x-ray was also done for some patients. Magnetic resonance imaging (MRI) brain was done for symptomatic patients. Complete blood count (CBC), liver function test (LFT), kidney function test (KFT) were evaluated upfront. Tumor markers like alpha-fetoprotein (AFP), beta subunit of human chorionic gonadotropin (βHCG), and lactate dehydrogenase (LDH) was evaluated for every patient initially and also during therapy. Pulmonary function test (PFT) was performed prior to start of chemotherapy in almost all patients. Sperm banking was offered to all adult male patients. Staging and risk categorization was done as per American Joint Committee on Cancer (AJCC) 7th edition and risk categorization on the basis of International Germ Cell Cancer Collaborative Group (IGCCCG) [3, 4].

A written informed consent was obtained prior to chemotherapy and surgery. Surgical procedures were evaluated. It was either biopsy initially to unilateral oophorectomy (fertility sparing surgery) or total abdominal hysterectomy and bilateral salpingo-oophorectomy in females. In males, biopsy for upfront inoperable disease or high inguinal unilateral orchidectomy was the procedure performed. The tissues were evaluated primarily with hematoxylin and eosin stain; however, IHC was evaluated wherever needed. Patients were treated with the standard chemotherapy protocols. Patients warranting chemotherapy were put on BEP regimen (Bleomycin 30 units day 1, day 8, day 15, Etoposide 100 mg/m² and Cisplatin 20 mg/m² on day 1 to 5 every three weeks). Chemotherapy regimen was changed to EP (Etoposide 100 mg/m² and Cisplatin 20 mg/m² on days 1 to 5 every three weeks) after 4 cycles of BEP in patients who had indications for more than four cycles of chemotherapy. Bleomycin was omitted in patients with abnormal pulmonary function test. Chemotherapy was administered for 4-6 cycles in majority of the patients. Patients were reviewed for toxicities before every cycle of chemotherapy. Toxicity was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0) [5]. Response evaluation was done in all patients after three chemotherapy cycles and after completion of all defined cycles as per stage with tumor markers (AFP, βHCG and LDH), ultrasonography or CECT of the abdomen and pelvis.

**II Follow Up**

All patients were advised three monthly follow up during the first 2 years followed by six monthly thereafter. Physical examination, marker evaluation as well as chest radiograph and CT scan of abdomen and pelvis were performed.

**III Evaluation**

Complete remission was taken as normalisation of tumor markers and resolution of tumor mass on CT scan. Progressive disease were defined as rising markers post treatment normalisation, new lesion on radiological examination, and pathologically proven new lesion.

**IV Statistical Analysis**

The Statistical Package for the Social Sciences (IBM SPSS version 25 for Windows) was used for statistical analysis. The descriptive statistics were used to characterize the patient population. Chi-square test and Kaplan Meier survival curves were plotted for disease-free survival (DFS) and overall survival (OS). Cox regression model was used for univariate analysis and multivariate analysis of prognostic factors. The prognostic factors having statistically significant p-value in univariate analysis were included in multivariate analysis. A p-value of < 0.05 considered statistically significant in all performed analysis. Disease-free survival was defined as time from diagnosis until recurrence (local or systemic) whereas overall survival was defined as time from diagnosis to death or last follow-up.

**Results**

**I Patient’s Characteristics**

Total of 75 patients with germ cell tumor (GCT) were analysed, the distribution of males and females were 50.7% and 49.3% respectively. The median age of presentation of males and females were 31 years and 15 years respectively. In males (n=38) most common involved age group
was 31-40 years followed by 21-30 years, 11-20 years, 41-50 years, 1-10 years, and > 50 years as 31.6%, 28.9%, 10.5%, 10.5%, 10.5%, and 7.9% respectively. In females (n=37) most common involved age group was 11-20 years followed by 21-30 years, 1-10 years, 31-40 years, 41-50 years, and > 50 years as 62.2%, 16.2%, 13.5%, 2.7%, 2.7%, and 2.7% respectively. Epidemiological details are given in (Table 1). Most common presenting symptom was testicular mass followed by neck node, hemoptysis, sacral mass, abdominal pain, abdominal pain and lump as 71.1%, 7.9%, 5.3%, 5.3%, 5.3%, and 5.3% respectively in males. In females’ abdominal pain, abdominal pain and lump, sacral mass, shortness of breath, and bleeding per vagina were 45.9%, 40.5%, 5.4%, 5.4%, and 2.7% respectively. The ECOG PS 0, 1, 2, and 3 were 18.9%, 35.1%, 35.1%, 10.8% respectively.

Table 1: Characteristics of patients of malignant germ cell tumors.

| Characteristics                  | Male (N=38) | N %  | Female(N=37) | N %  |
|----------------------------------|------------|------|--------------|------|
| Age group                        |            |      |              |      |
| 1 - 10 years                     | 4          | 10.5%| 5            | 13.5%|
| 11 - 20 years                    | 4          | 10.5%| 23           | 62.2%|
| 21 - 30 years                    | 11         | 28.9%| 6            | 16.2%|
| 31 - 40 years                    | 12         | 31.6%| 1            | 2.7% |
| 41 - 50 years                    | 4          | 10.5%| 1            | 2.7% |
| > 50 years                       | 3          | 7.9% | 1            | 2.7% |
| ECOG PS                          |            |      |              |      |
| ECOG_0                           | 12         | 31.6%| 7            | 18.9%|
| ECOG_1                           | 15         | 39.5%| 13           | 35.1%|
| ECOG_2                           | 7          | 18.4%| 13           | 35.1%|
| ECOG_3                           | 4          | 10.5%| 4            | 10.8%|
| Presenting complains             |            |      |              |      |
| Abdominal pain                   | 2          | 5.3% | 17           | 45.9%|
| Abdominal pain and lump          | 2          | 5.3% | 15           | 40.5%|
| Bleeding per vagina              | 0          | 0.0% | 1            | 2.7% |
| Hemoptysis                       | 2          | 5.3% | 0            | 0.0% |
| Neck node                        | 3          | 7.9% | 0            | 0.0% |
| Sacral mass                      | 2          | 5.3% | 2            | 5.4% |
| Shortness of breath              | 0          | 0.0% | 2            | 5.4% |
| Testicular swelling              | 27         | 71.1%| 0            | 0.0% |
| Diagnosis                        |            |      |              |      |
| Dysgerminoma                     | 0          | 0.0% | 17           | 45.9%|
| Mediastinal germ cell tumor      | 0          | 0.0% | 2            | 5.4% |
| Non dysgerminoma                 | 0          | 0.0% | 16           | 43.2%|
| Non seminoma                     | 17         | 44.7%| 0            | 0.0% |
| Seminoma                         | 19         | 50.0%| 0            | 0.0% |
| Sacrococcygeal teratoma          | 2          | 5.3% | 2            | 5.4% |
| Histological subtypes            |            |      |              |      |
| Embryonal cell carcinoma         | 5          | 13.2%| 3            | 8.1% |
| Choriocarcinoma                  | 1          | 2.6% | 0            | 0.0% |
| Immature teratoma                | 0          | 0.0% | 5            | 13.5%|
| Mature teratoma                  | 0          | 0.0% | 0            | 0.0% |
| Mixed GCT                        | 11         | 28.9%| 3            | 8.1% |
| Endodermal sinus / yolk sac tumor| 2          | 5.3% | 9            | 24.3%|
| Seminoma                         | 19         | 50.0%| 0            | 0.0% |
| Dysgerminoma                     | 0          | 0.0% | 17           | 45.9%|
| Metastasis                       |            |      |              |      |
| No metastasis                    | 20         | 52.6%| 31           | 83.8%|
| Ascites                          | 0          | 0.0% | 4            | 10.8%|
| Inguinal lymph nodes             | 2          | 5.3% | 0            | 0.0% |
| Liver                            | 4          | 10.5%| 1            | 2.7% |
| Lung                             | 9          | 23.7%| 1            | 2.7% |
| Supraclavicular lymph nodes      | 3          | 7.9% | 0            | 0.0% |
| Metastasis at diagnosis          |            |      |              |      |
| Yes                              | 18         | 47.4%| 6            | 16.2%|
| No                               | 20         | 52.6%| 31           | 83.8%|
| S- group                         |            |      |              |      |
| S0                               | 0          | 0.0% | 0            | 0.0% |
| S1                               | 17         | 44.7%| 18           | 48.6%|
| S2                               | 17         | 44.7%| 16           | 43.2%|
| S3                               | 4          | 10.5%| 3            | 8.1% |
| Risk group                       |            |      |              |      |
| Good                             | 17         | 44.7%| 18           | 48.6%|
At the time of presentation, 47.3% (18) males and 16.2% (6) of female patients had metastatic disease. The most common site of metastasis in males was lung followed by liver, supraclavicular lymph nodes, and inguinal lymph nodes as 23.7%, 10.5%, 7.9%, and 5.3% respectively. In females, the most common metastasis was ascites followed by liver and lung as 10.8%, 2.2% and 2.7% respectively. The median value at presentation of AFP, βHCG, and LDH were 66.5 ng/ml, 673 mIU/ml, and 458 U/L respectively in males and 152 ng/ml, 655 mIU/ml, and 458 U/L respectively in females. The overall median value of AFP, βHCG, and LDH were 3 ng/ml, 2 mIU/ml, and 255 U/L respectively. Post treatment the median value of maximum tumor size was 6 cm (3.2-12.3) in males and 9 cm (3.2-21.6) in females. Tumor details, serum tumor markers, and follow-up duration depicted in (Table 2).

The median numbers of chemotherapy cycles were 4 (range 1-6) in both male and females. In all patients who received more than 4 cycles of chemotherapy, their chemotherapy regimen was changed to EP after four cycles of BEP. Post-chemotherapy toxicity analysis in males revealed that 42.1% developed mild grade I complications. Grade III toxicities including diarrhea, mucositis, neutropenia, anemia and febrile neutropenia was seen in 18.4%, 7.9%, 7.9%, 10.5% and 13.2% respectively.

In females grade I toxicity was seen in 53% patients. Grade III diarrhea, mucositis, neutropenia and febrile neutropenia was seen in 7.7%, 10.4%, 13.1% and 15.8% patients respectively. Post treatment the overall median value of AFP, βHCG, and LDH were 3 ng/ml, 2 mIU/ml, and 287 U/L respectively. In males the median post treatment AFP, βHCG, and LDH were 4.1 ng/ml, 2.9 mIU/ml, and 312 U/L respectively. In females post treatment AFP, βHCG, and LDH were 2.2 ng/ml, 1.4 mIU/ml, and 255 U/L respectively. Histopathological analysis grossly revealed that in males 44.7%, 50%, and 5.3% of cases were of non-seminoma, seminoma, and sacrococegal teratoma respectively. In females 45.9%, 43.2%, 5.4%, and 5.4% were dysgerminoma, non-dysgerminoma, sacrococegal teratoma, and mediastinal GCT respectively. Histopathological diagnosis along with immunohistochemistry in certain cases showed that seminoma, mixed GCT, embryonal cell carcinoma, endodermal sinus tumor/yolk sac tumor, and choriocarcinoma were 50%, 28.9%, 13.2%, 5.3%, and 2.6% respectively. Immunohistochemistry (IHC) reports were available 30.6% of patients. In female’s dysgerminoma, endodermal sinus tumor/yolk sac tumor, immature teratoma, mixed GCT, embryonal cell carcinoma were 45.9%, 24.3%, 13.5%, 8.1%, and 8.1% respectively. The median value of maximum tumor size was 6 cm (3.2-12.3) in males and 9 cm (3.2-21.6) in females. Tumor details, serum tumor markers, and follow-up duration depicted in (Table 2).

### Table 1: Patient Characteristics

| Intermediate | High | No | Yes | No |
|--------------|------|----|-----|----|
| 13           | 34.2%| 13 | 35.1%|
| 8            | 21.1%| 6  | 16.2%|

### Table 2: Surgical details

| Surgical details | Biopsy | Cytoreductive surgery | Left high inguinal orchidectomy | Left salpingo-ooophorectomy | Right high inguinal orchidectomy | Right salpingo-ooophorectomy | TAH + BSO |
|------------------|--------|----------------------|-------------------------------|-----------------------------|--------------------------------|----------------------------|----------|
|                   | 6      | 1                    | 11                           | 0                           | 20                            | 0                           | 0        |
|                   | 15.8%  | 2.6%                 | 28.9%                         | 0.0%                        | 52.6%                         | 0.0%                        | 16.2%    |
|                   | 4      | 3                    | 0                             | 12                          | 0                             | 12                          | 32.4%    |

### Table 3: Upfront surgery

| Stage | Yes | No |
|-------|-----|----|
| Stage I | 5   | 15.7% |
| Stage II | 14  | 36.8% |
| Stage III | 19  | 50.0% |
| Stage IV | 0   | 0.0%  |

### Table 4: Treatment defaulted

| ECOG PS: Eastern Cooperative Oncology Group Performance Scale | Yes | No |
|------------------------------------------------------------|-----|----|
| S group: serum tumor marker group | | |
| GCT: germ cell tumor | | |
| TAH and BSO: total abdominal hysterectomy and bilateral salpingo-ooophorectomy | | |
| BEP: bleomycin, etoposide, cisplatin | | |
Table 2: Details of tumor markers, tumor description, age, and follow-up.

|                | Age (years) | Maximum size tumor (cm) | AFP  | βHCG | LDH   | Follow up (months) |
|----------------|-------------|-------------------------|------|------|-------|--------------------|
| Male (N=38)    |             |                         |      |      |       |                    |
| Median         | 31.00       | 6.00                    | 4.10 | 2.95 | 312.00| 38.50              |
| Minimum        | 1           | 3.20                    | 0.10 | 0.20 | 143.00| 1.00               |
| Maximum        | 61          | 12.30                   | 47.00| 32.00| 685.00| 120.00             |
| Female (N=37)  |             |                         |      |      |       |                    |
| Median         | 15.00       | 9.00                    | 2.20 | 1.40 | 255.00| 33.00              |
| Minimum        | 2           | 3.20                    | 0.10 | 0.01 | 168.00| 17.00              |
| Maximum        | 60          | 21.60                   | 40.00| 300.00| 1718.00| 81.00              |

AFP: alpha-fetoprotein; βHCG: beta subunit of human chorionic gonadotropin; LDH: lactate dehydrogenase.

II Survival Analysis

The median follow-up duration was 34 months (12-120). Twenty-four (32%) patients had a recurrence until last follow up in March 2020. The median DFS and OS were 57 months (95% CI: 51.826 - 62.174) and 71 months (95% CI: 67.475 - 74.525). In both groups the 3-year and 5-year DFS was 77.4% and 42.8% respectively whereas 3-year and 5-year OS was 81.3% and 67% respectively. DFS was statistically significantly differing according to risk group (Log Rank: p < 0.001) (Figure 1), histopathological subtypes (Log Rank: p < 0.001), stage (Log Rank: p = 0.002). OS was also statistically significantly differing according to risk group (Log Rank: p = 0.001), histopathological subtypes (Log Rank: p < 0.001), stage (Log Rank: p = 0.001) (Figure 2).

![Figure 1](image1.png)

**Figure 1:** Disease-free survival in months with risk group classification; Log Rank (Mantel Cox) p < 0.001.

![Figure 2](image2.png)

**Figure 2:** Overall survival in months according to stage; Log rank (Mantel Cox) p = 0.001.
III Analysis of Prognostic Factors

Univariate analysis using Cox-regression showed that histopathological subtypes, metastatic status at diagnosis, risk group, upfront surgery, stage were affecting the DFS and OS (p < 0.05) in addition to that OS is also influenced by ECOG PS at diagnosis (p = 0.044). Multivariate analysis showed that the histological subtypes (p = 0.001) and risk groups (p = 0.029) are the independent prognostic factors for DFS, while metastatic status at presentation (p = 0.037), upfront surgical intervention (p = 0.039), and histopathological subtypes (p = 0.009) were the independent prognostic factor for OS details depicted in (Table 3).

Table 3: Univariate and multivariate analysis of factors associated with disease-free survival (DFS) and overall survival.

| Characteristics | Univariate analysis (DFS) | Multivariate analysis (DFS) |
|-----------------|--------------------------|----------------------------|
|                 | HR  | 95% CI | p-value | HR  | 95% CI | p-value |
| Metastatic status at diagnosis | 6.436 | 2.357-17.573 | < 0.001 | 1.112 | 0.260-4.905 | 0.871 |
| Risk group | 4.185 | 2.199-7.963 | < 0.001 | 2.607 | 1.103-6.162 | 0.029 |
| Upfront surgery | 3.385 | 1.516-7.560 | 0.003 | 2.101 | 0.773-5.710 | 0.146 |
| Stage | 2.264 | 1.315-3.898 | 0.003 | 1.054 | 0.458-2.427 | 0.901 |
| Histopathological subtypes | 0.708 | 0.612-0.820 | < 0.001 | 0.740 | 0.623-0.879 | 0.001 |
| ECOG-PS | 1.516 | 0.975-2.357 | 0.065 |

Discussion

GCTs are uncommon tumor. The incidence of GCT is increasing. There is a lack of recent data from India on epidemiology of GCT. The male and female distribution was equal in our study. In this study, the median age at diagnosis was 31 years and 15 years in males and females. The findings from other Indian study by Joshi A et al. reported that the median age for seminomatous and nonseminomatous GCT were 28 years and 39 years respectively in males [6]. Mustafa SA et al. in their study reported the median age of female GCT as 22 years [8]. SS Chavan et al. reported that the median age for seminomatous and nonseminomatous GCT were 28 years and 40 years in males and 11 years in females [6]. Testicular mass and abdominal pain was the most common presenting symptoms in males and females respectively in our study. 47.3% and 16.7% were metastatic disease at presentation for males and females respectively. The most common metastatic site was lungs; other studies also reported findings to consistent with our study [6, 8].

Western literature reported the similar epidemiological findings to that of our study especially considering male patients with median age at diagnosis of 28 years, 56% of the male GCT patients were in metastatic stage [11]. In our study male patient were in good, intermediate, and poor risk as 44.7%, 34.2%, and 21.1% respectively and female patients on risk group stratification were in 48.6%, 35.1%, and 16.2% respectively. Vasconcellos et al. reported similar risk group distribution of patients for male GCT. The most common histological subtype was seminoma in males and dysgerminoma in females similar to other studies [6, 7, 10]. In this study seminoma and dysgerminoma was associated with raised AFP and LDH, nonseminoma and non-dysgerminoma was associated with raised AFP, βHCG, and LDH, which was consistent with other aforementioned studies. The median number of chemotherapy cycles were 6 in both male and female patients. The median size of the tumor was 6 cm in males and 9 cm in females, which were consistent with other studies [6, 9]. The incidence of febrile neutropenia was less in this study, compared to study by Joshi et al. This may be due to prophylactic use of GCSF in our study. The median delay due to chemotherapy toxicities between the cycles were 11 days in males and 8 days in females. In this study, the recurrence was 32% during the median follow-up of 34 months. Other studies reported recurrence rate from 12-30% [8, 11, 12].

We observed in this study that the median DFS and OS were 57 and 71 months respectively. Five years DFS and OS were 42.8% and 67% respectively. This survival data was not in concordance with the other studies probably because most of our patients were in advanced stage, poor risk groups, and of unfavourable histology. If alone the 5-year survival was seen for all stages excluding stage IV, the survival was good and comparable to other studies indicating the effectiveness of platinum based systemic chemotherapy that was given to all patients. This study highlights that most of the patients presenting to a tertiary care center are in advanced stage with high nodal burden disease. All this ultimately leads to the suboptimal response and suboptimal survival in patients of GCT. However, those who presented in early stage, with favourable histology and underwent multidisciplinary cancer care enjoyed a good long survival.

Conclusion

GCTs are most frequently diagnosed in adolescence and young patients. If diagnosed earlier, a well-orchestrated multidisciplinary management...
approach improves the outcome and survival. In developing countries most of the cases of GCT presents at advanced stage with high nodal burden. It must be emphasised that the GCT is primarily a disease of young and adolescents, therefore these groups of patients should undergo proper investigations and referral, if any suspicion of malignancy is encountered.

**Ethical Approval**

The Institutional Research Committee (IRC) at the All India Institute of Medical Sciences, Patna has approved the study (Ref No. AIIMS/Pat/IRC/2020/591, dated 3/11/2020).

**Data Availability**

The data sets used or analysed during the current study are available from the corresponding author on reasonable request.

**Conflicts of Interest**

None.

**Funding**

None.

**Author Contributions**

Study concept: Dr. PS; study design: Dr. DS, Dr. JKP, Dr. BK; data acquisition: Dr. DS, Dr. AM; data analysis: Dr. DS; data interpretation: Dr. DS; manuscript preparation: all authors; manuscript review: all authors.

**Abbreviations**

AJCC: American Joint Committee on Cancer

AFP: Alpha-Fetoprotein

BEP: Bleomycin, Etoposide, Cisplatin

βHCG: Beta Subunit of Human Chorionic Gonadotropin

CBC: Complete Blood Count

CTCAE: Common Terminology Criteria for Adverse Events

CECT: Contrast-Enhanced Computed Tomography

CI: Confidence Interval

DFS: Disease-Free Survival

ECOG PS: Eastern Cooperative Oncology Group Performance Status

EUROCARE: European Cancer Registry Based Study on Survival and Care of Cancer Patients

EP: Etoposide, Cisplatin

GCT: Germ Cell Tumor

IGCCCG: International Germ Cell Cancer Collaborative Group

IHC: Immunohistochemistry

KFT: Kidney Function Test

LDH: Lactate Dehydrogenase

LFT: Liver Function Test

MRI: Magnetic Resonance Imaging

NACT: Neoadjuvant Chemotherapy

NST: Non Seminomatous

OS: Overall Survival

PFT: Pulmonary Function Test

ST: Seminomatous

**REFERENCES**

1. Lobo J, Gillis AJM, Jeronimo C, Henrique R, Looijenga LHJ et al. (2019) Human germ cell tumors are developmental cancers: Impact of epigenetics on pathobiology and clinic. *Int J Mol Sci* 20: 258. [Crossref]

2. Cecchetto G (2014) Gonadal germ cell tumors in children and adolescents. *J Indian Assoc Pediatr Surg* 19: 189‐194. [Crossref]

3. Edge SB, Compton CC, Fritz AG, Green FL (2010) AJCC cancer staging manual, 7th edition. *Springer*

4. Meisel JL, Woo KM, Sudarsan N, Eng J, Patil S et al. (2015) Development of a risk stratification system to guide treatment for female germ cell tumors. *Gynecol Oncol* 138: 566‐572. [Crossref]

5. National Cancer Institute. CTCAE toxicity criteria version 5.0.

6. Joshi A, Zanwar S, Shetty N, Patil V, Noronha V et al. (2016) Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India. *Indian J Cancer* 53: 313-316. [Crossref]

7. Mustafa SA, Mitla V, Banday SZ, Kuchay S (2017) Profile of Testicular Germ Cell Tumors in Kashmir: A Retrospective Analysis. *Int J Sci Stud* 5:183-186.

8. Lakshmanan M, Jain K, Garg S, Gupta S (2018) Germ Cell Tumor Ovary: an Institutional Experience of Treatment and Survival Outcomes. *Indian J Surg Oncol* 9: 215-219. [Crossref]

9. Chavan SS, Toppo SM (2019) Study of 92 cases of ovarian germ cell tumour at tertiary health care centre. *Indian J Pathol Oncol* 6: 464-470.

10. Kaatsch P, Häfner C, Calaminus G, Blettner M, Tulla M (2015) Pediatric Germ Cell Tumors From 1987 to 2011: incidence Rates, Time Trends, and Survival. *Pediatrics* 135: e136-e143. [Crossref]

11. Vasconcellos VF, Bastos DA, Lima Pereira AA, Watarai GY, Pereira BR et al. (2019) Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil. *J Glob Oncol* 5: 1-8. [Crossref]

12. Fonseca A, Frazier AL, Shaikh F (2019) Germ Cell Tumors in Adolescents and Young Adults. *J Oncol Pract* 15: 433-441. [Crossref]